Investigation area: Advanced Therapies and Biomedical Technologies

The area includes national and international reference groups in the field of pharmacology, advanced therapies, biomaterials and technologies applied to the biosanitary field whose objective is to design and implement new therapies and products that can contribute to the diagnosis or treatment of diseases for which there is no fully effective therapy.
The objectives of the area are:

a) To develop and promote new modulated drugs for the treatment of diseases. Study genetic polymorphisms that affect the efficacy, safety and dosage of drugs. Preparation of clinical practice guidelines. Safe practices in the use of medications. Stability study of drugs in the conditions of clinical use.

b) Generate new Advanced Therapies drugs that allow a treatment based on cell and tissue regeneration. Design new highly biomimetic biomaterials for use in tissue engineering. Implement quality controls at the histological, biomechanical, optical, genetic and functional level of the new products generated for future clinical use. Transfer new advanced therapy products to the clinic in accordance with the standards of the Drug Agencies.

c) Develop new protocols for the treatment of prevalent human pathologies based on new biomedical technologies, advanced surgical techniques, in vitro reproduction, diagnosis through nuclear and molecular medicine and other advanced diagnosis and treatment strategies.

Line: Pharmacology. Organic synthesis. Hospital pharmacotherapeutic follow-up. Safe practice.

Line B: Tissue Engineering and Advanced Therapies. biomaterials. Odontology.

Line C: Biomedical technology and devices.